Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04965753 · ClinicalTrials.gov registry record · Phase 1
FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors
A Phase 1 study, sponsored by Foghorn Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
NCT04965753 is a Phase 1 study that was terminated before completion, run by Foghorn Therapeutics. The registered enrollment target is 55 participants.
The verdict
NCT04965753, a Phase 1 study, was terminated before completion, sponsored by Foghorn Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
This Phase 1, multicenter, open-label, dose escalation and expansion study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-609 given intravenously in subjects with advanced synovial sarcoma or advanced SMARCB1-loss tumors.
Interventions
- DRUG FHD-609
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2021-08-17 |
| Est. Completion | 2023-12-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04965753
The ClinicalTrials.gov registry entry for NCT04965753 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Foghorn Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FHD-609 is the first listed.
NCT04965753 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04965753 about?
NCT04965753 is a clinical study titled "FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors". This Phase 1, multicenter, open-label, dose escalation and expansion study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-609 given intravenously in subjects with advanced synovial sarcoma or advanced SMARCB1-los...
What is the current status of trial NCT04965753?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2021-08-17. Estimated completion is 2023-12-04.
What interventions are being tested in trial NCT04965753?
The interventions under investigation include: FHD-609 (DRUG).
Who is sponsoring clinical trial NCT04965753?
This trial is sponsored by Foghorn Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.